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Introduction
Endocrine therapy is increasingly understood as the con-
ceptual basis for the future treatment and prevention of
breast cancer. Endocrine agents have considerably
changed the approach to targeted treatment during the
past two decades, and select endocrine agents have
advanced the goal of preventing breast cancer. Progress
has been made because of a vigorous interaction between
laboratory scientists and the clinical trials community. The
result is that hundreds of thousands of women who would
have died now live longer, healthier lives. Breast Cancer
Research is therefore launching a new section on
endocrinology and hormone therapy to invigorate this
exchange and challenge our readers with novel concepts
that might result in enhanced survival in breast cancer.
As we have done previously in areas of special interest to
the breast cancer community, we will mark the new
section with a series of thematic reviews on the evolution
of progress in endocrine therapy. One of these reviews
will focus on antioestrogens and aromatase inhibitors. The
ubiquitous application of the antioestrogen tamoxifen
since the 1970s has radically improved the prospects for
breast cancer patients and, as a result, it has generated
enormous interest in new approaches to targeted therapy.
All earlier antioestrogens or aromatase inhibitors failed to
become accepted into general use because of excessive
toxicity that prevented long-term administration. The evolv-
ing clinical trials ultimately demonstrated that, to save
lives, long-term administration over 5 years is required [1].
However, key to the remarkable advances in endocrine
therapy was the identification of the oestrogen receptor
(ER) as the mechanism and catalyst for universal oestro-
gen action. Fortunately, the ER represents a critical
growth and survival pathway in breast tumours, and so
blocking the ER with an antioestrogen is selectively toxic
to the tumour. The ER thus became an early model for
molecular medicine [2]. Today, endocrine agents that
exploit the ER target in one way or another are ubiquitous
in medicine, with clinical studies of the use of aromatase
inhibitors at all stages of ER-positive breast cancer [3] and
testing of selective oestrogen receptor modulators
(SERMs) to prevent breast cancer, osteoporosis and
coronary heart disease.
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We will also discuss the effect of hormone replacement
therapy (HRT) on breast cancer. Large clinical studies
have demonstrated that there is a significant reduction in
osteoporotic fractures and, paradoxically, colon cancer in
women who use oestrogen plus progestin replacement
(HRT), but there is an unacceptable increase in breast
cancer, dementia, cardiovascular disease and clotting
episodes [4,5]. The discovery of new designer oestro-
gens or SERMs has now become a priority in medicine,
and there are opportunities to develop new progestins.
The goal is to improve quality of life without carcinogenic
potential.
Another review may look at the new trend in antihormone
or SERM therapy and endocrine drug resistance. The use
of SERMs to prevent breast cancer, osteoporosis or coro-
nary heart disease will not necessarily be limited to 5 years
of treatment, but long-term use may increase the potential
to develop endocrine-resistant breast cancer. Thus, the
challenge for the future is fast becoming how to address
endocrine drug resistance and the identification of novel
targets to treat tumours resistant to SERMs. Not surpris-
ingly, extended endocrine therapy eventually results in
drug resistance but, uniquely, SERM-stimulated breast
tumour growth continues to depend on the ER in the
signal transduction pathway. A pure antioestrogen, that
retargets and destroys the ER, is already available as a
new second line treatment for tamoxifen-resistant breast
cancer [6,7].
Remarkable and certainly worth some scrutiny is the newly
emerging information showing that the oestradiol–ER
complex may not only control the survival of the breast
cancer cell but also induce its death following exhaustive
endocrine therapy. Until now, the only remaining option for
the patient developing antihormonal resistance has been
cytotoxic chemotherapy. Clinical studies [8] demonstrate
that the reintroduction of high-dose oestrogen following
exhaustive endocrine therapy results in dramatic tumour
responses. Laboratory studies also demonstrate that
tumour regression can occur if physiological levels of
oestrogen are used to treat long-term SERM resistance,
and the few tumours that regrow are again responsive to
tamoxifen treatment [9]. The clinical question could soon
become, ‘Can low-dose oestrogen therapy be incorpo-
rated into the clinical treatment plan, cause tumour regres-
sion and reactivate antihormonal sensitivity?’
If the mechanism of ER-mediated apoptosis is discovered,
then this could improve response rates in breast cancer.
Women with antihormone-resistant ER-positive tumours
may respond to a cocktail of agents targeted at tyrosine
kinases so that the ER becomes more central to survival.
In other words, the aim would be to create multiple blocks
to survival so that oestrogen-induced death becomes the
only cellular option. Success here would double the
response rate for endocrine treatment of breast cancer. If
that were not enough, it would not be unreasonable to
suggest that if the mechanism of ER-mediated apoptosis
was discovered then it could open the door to innovation
in targeted drugs for the death pathway of all cancer cells.
Obviously, there is much to be done before we can begin
to target the treatment of all ER-negative tumours, and it is
reasonable to predict that issues of selectivity and sys-
temic toxicity will be central to success. Nevertheless, who
would have believed, when the principle of SERM action
was established first in the laboratory and translated to the
clinic, that this would act as the catalyst for the develop-
ment of selective modulators for each member of the
steroid receptor superfamily. Knowledge in one discipline
can today be rapidly exported to enhance advances in
other areas.
The goal of Breast Cancer Research’s new section on
endocrinology and hormone therapy is not to replicate
existing reviews in the endocrinology of breast cancer but
to invigorate a new generation of investigators to take the
lessons learned, whether they were good or bad, and
apply the knowledge to new areas of investigation. The
section will not necessarily provide answers but will
instead aim to challenge our readers with novel concepts
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